• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Infliximab biosimilar CT-P13 in Crohn's disease.

作者信息

Gecse Krisztina B, D'Haens Geert R

机构信息

Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, Netherlands.

Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, Netherlands.

出版信息

Lancet. 2019 Apr 27;393(10182):1671-1672. doi: 10.1016/S0140-6736(18)32778-8. Epub 2019 Mar 28.

DOI:10.1016/S0140-6736(18)32778-8
PMID:30929894
Abstract
摘要

相似文献

1
Infliximab biosimilar CT-P13 in Crohn's disease.英夫利昔单抗生物类似药CT-P13用于克罗恩病的治疗
Lancet. 2019 Apr 27;393(10182):1671-1672. doi: 10.1016/S0140-6736(18)32778-8. Epub 2019 Mar 28.
2
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.比较 CT-P13 生物类似药与原研英夫利昔单抗治疗活动性克罗恩病患者的疗效和安全性：一项国际、随机、双盲、3 期非劣效性研究。
Lancet. 2019 Apr 27;393(10182):1699-1707. doi: 10.1016/S0140-6736(18)32196-2. Epub 2019 Mar 28.
3
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.在炎症性肠病处于缓解期的患者中，由原研英夫利昔单抗转换为生物类似药 CT-P13 后的血清浓度（SECURE）：一项开放标签、多中心、四期非劣效性试验。
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412. doi: 10.1016/S2468-1253(18)30082-7. Epub 2018 Mar 30.
4
Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.新型英夫利昔单抗生物类似药CT-P13诱导治疗克罗恩病和溃疡性结肠炎的疗效——单中心经验
Expert Opin Biol Ther. 2015;15(9):1257-62. doi: 10.1517/14712598.2015.1064893. Epub 2015 Jul 2.
5
Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.英夫利昔单抗生物类似药CT-P13治疗在维持克罗恩病和溃疡性结肠炎缓解方面有效且安全——来自单一中心的经验
Expert Opin Biol Ther. 2017 Nov;17(11):1325-1332. doi: 10.1080/14712598.2017.1363885. Epub 2017 Aug 18.
6
Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease.生物类似药英夫利昔单抗用于儿童克罗恩病的诱导治疗
J Pediatr Gastroenterol Nutr. 2017 Sep;65(3):285-288. doi: 10.1097/MPG.0000000000001643.
7
CT-P13 biosimilar is non-inferior to infliximab.
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):326. doi: 10.1038/s41575-019-0155-5.
8
Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.在炎症性肠病患者中，将英夫利昔单抗维持治疗转换为英夫利昔单抗生物类似药治疗。
Scand J Gastroenterol. 2017 Dec;52(12):1348-1353. doi: 10.1080/00365521.2017.1369561. Epub 2017 Aug 24.
9
Long-Term Clinical Outcomes After Switching from Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease.炎症性肠病患者从类克转换为生物类似药CT-P13后的长期临床结局
Dig Dis Sci. 2017 Nov;62(11):3117-3122. doi: 10.1007/s10620-017-4661-4. Epub 2017 Jun 30.
10
Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.相似但不相同：克罗恩病患者从CT-P13换用SB2英夫利昔单抗生物类似药后出现斑块状银屑病加重
Inflamm Bowel Dis. 2020 Jul 17;26(8):e83-e84. doi: 10.1093/ibd/izaa128.

引用本文的文献

1
Therapeutic regimen of Crohn's disease: effect of Infliximab combined with mesalazine on intestinal flora and inflammatory indexes in patients.克罗恩病的治疗方案：英夫利昔单抗联合美沙拉嗪对患者肠道菌群及炎症指标的影响
BMC Gastroenterol. 2025 Sep 29;25(1):687. doi: 10.1186/s12876-025-04236-9.
2
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease.炎症性肠病中抗肿瘤坏死因子药物的生物类似药
Biologics. 2020 Jan 10;14:1-11. doi: 10.2147/BTT.S236433. eCollection 2020.